Article Details

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of ...

Retrieved on: 2022-04-20 22:58:33

Tags for this article:

Click the tags to see associated articles and topics

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of .... View article details on HISWAI: https://pipelinereview.com/index.php/2022042080739/Antibodies/Ultragenyx-Announces-First-Patient-Dosed-in-Pivotal-Phase-2/3-Clinical-Study-of-Setrusumab-UX143-for-the-Treatment-of-Osteogenesis-Imperfecta.html

Excerpt

Details: Category: Antibodies: Published on Wednesday, 20 April 2022 18:52 ... Setrusumab is a fully human monoclonal antibody that inhibits ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up